ILife Consulting Appoints Tanja Ouimet as Executive Director

Paris, France – February 3, 2026 – ILife Consulting, a strategic CRO partner supporting biotech companies in the clinical development of innovative therapies, today announced the appointment of Tanja Ouimet, PhD, as its new Executive Director.

She succeeds Marina Iché, Founder and Chief Executive Officer, who has successfully led the company since its creation in 2013 and will continue to support ILife Consulting during a two-month transition.

This leadership transition marks an important milestone for the organisation as it enters a transition phase following its recent acquisition by the Comac Medical Group. Together, the organisations are building a strong Pan-European CRO platform with expertise in complex early-phase clinical development strategy and execution in oncology and innovation-driven programs.

Tanja Ouimet has been part of ILife Consulting for several years, most recently serving as Business & Strategy Director, where she played a central role in shaping the company’s strategic positioning, strengthening client partnerships, and supporting the expansion of its clinical development and innovation services, both within ILife Consulting and across the broader Comac Medical Group ecosystem.

With more than 20 years of experience spanning discovery, preclinical and clinical development, Tanja brings a rare combination of scientific depth, operational excellence, and strategic leadership. Her background spans CRO operations, clinical development strategy, business development, and executive management, with a strong track record in overseeing international Phase I/II clinical trials, managing complex outsourcing models, and supporting biotech and pharma companies at critical value-creation inflection points.

“I am honored to take on the role of Executive Director of ILife Consulting at such a defining moment for the company,” said Tanja Ouimet, PhD. “As part of Comac Medical Group, we are uniquely positioned to combine agility, scientific excellence, and expanded international capabilities. Our ambition is clear: to be a trusted strategic partner for innovative companies as they transform scientific breakthroughs into meaningful therapies for patients. ”

Before joining ILife Consulting, Tanja held senior leadership roles in the life sciences industry, including Chief Operating Officer and Director of Clinical Development at Pharmaleads, where she led global clinical programs, supported licensing transactions with a potential total value exceeding €100 million, and worked closely with boards, investors, and strategic partners. She also serves as a strategic advisor and board member to several innovative biotech companies.

“Tanja has been a key contributor to ILife Consulting’s development over the past years,” said Marina Iché, Founder of ILife Consulting. “Her deep understanding of our clients’ needs and challenges, combined with her leadership experience and strategic vision, makes her ideally suited to support the organisation’s continued evolution within the Comac Medical Group.”

Under Tanja Ouimet’s leadership, teams will continue to deliver high-value strategic CRO support to biotech partners while leveraging the scale and geographical reach of the Comac Medical Group.

END

About ILife Consulting

ILife Consulting is a Paris-based CRO specialised in early-phase oncology and biotech

development. Since 2013, ILife has partnered with emerging biotech companies to deliver tailored, strategic, and operational support – from protocol design to full clinical trial execution, including first-in-human and multi-country studies. With deep expertise in oncology, rare diseases, novel therapeutic modalities, and complex regulatory environments, ILife accelerates timelines, optimises data quality, and helps its clients make confident, value-driven decisions. Trusted by biotech sponsors across Europe, ILife's senior team of scientific and clinical leaders is committed to delivering high-impact studies that bring innovation closer to patients.

www.Ilifeconsulting.com

About Comac Medical Group

Comac Medical Group is a pan-European, full-service CRO supporting small and medium-sized biopharma companies across early to late-phase drug development. With a strong footprint across Western, Central, and Eastern Europe, the group combines strategic expertise, operational scale, and deep therapeutic know-how to support complex development programs, particularly in oncology and rare diseases.

As part of its integrated platform, Comac Medical Group also provides early-phase clinical research capabilities through its FDA- and EMA-inspected Clinical Research Unit in Sofia, Bulgaria, supporting Phase I and bioavailability and bioequivalence studies.

Contact

Press -ATCG Partners

Marie Puvieux, press officer

[email protected]

+33 (0)6 10 54 36 72